CN115252521A - 一种祛皱保湿眼部精华液及其制备方法 - Google Patents
一种祛皱保湿眼部精华液及其制备方法 Download PDFInfo
- Publication number
- CN115252521A CN115252521A CN202210958430.9A CN202210958430A CN115252521A CN 115252521 A CN115252521 A CN 115252521A CN 202210958430 A CN202210958430 A CN 202210958430A CN 115252521 A CN115252521 A CN 115252521A
- Authority
- CN
- China
- Prior art keywords
- fullerene
- eye essence
- extract
- wrinkle
- moisturizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003020 moisturizing effect Effects 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title abstract description 14
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims abstract description 52
- 229910003472 fullerene Inorganic materials 0.000 claims abstract description 44
- 239000003906 humectant Substances 0.000 claims abstract description 26
- 239000002904 solvent Substances 0.000 claims abstract description 23
- 239000002562 thickening agent Substances 0.000 claims abstract description 21
- 239000002738 chelating agent Substances 0.000 claims abstract description 17
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-aminopropionic acid Natural products NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229940000635 beta-alanine Drugs 0.000 claims abstract description 11
- 239000011550 stock solution Substances 0.000 claims abstract description 10
- -1 beta-alanine modified fullerene Chemical class 0.000 claims abstract description 9
- 239000000284 extract Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000001816 cooling Methods 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 12
- 102000008186 Collagen Human genes 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 9
- 230000003750 conditioning effect Effects 0.000 claims description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 6
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 5
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 5
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 4
- 241001673966 Magnolia officinalis Species 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 229920006037 cross link polymer Polymers 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 claims description 3
- ROTFCACGLKOUGI-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-acetamidopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)CCNC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ROTFCACGLKOUGI-JYJNAYRXSA-N 0.000 claims description 3
- FDHNLHLOJLLXDH-JIYHLSBYSA-N (e)-3-(3-hydroxy-4-methoxyphenyl)-1-[2-hydroxy-6-methoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxyphenyl]prop-2-en-1-one Chemical compound C1=C(O)C(OC)=CC=C1\C=C\C(=O)C(C(=C1)OC)=C(O)C=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 FDHNLHLOJLLXDH-JIYHLSBYSA-N 0.000 claims description 3
- 241000590031 Alteromonas Species 0.000 claims description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 3
- LZDNBBYBDGBADK-KBPBESRZSA-N Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-KBPBESRZSA-N 0.000 claims description 3
- 229960003237 betaine Drugs 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 229940009714 erythritol Drugs 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 235000019414 erythritol Nutrition 0.000 claims description 3
- 229940076640 hesperidin methylchalcone Drugs 0.000 claims description 3
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 241000206575 Chondrus crispus Species 0.000 claims description 2
- 244000260524 Chrysanthemum balsamita Species 0.000 claims description 2
- 235000005633 Chrysanthemum balsamita Nutrition 0.000 claims description 2
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims description 2
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 244000050053 Rosa multiflora Species 0.000 claims description 2
- 235000000656 Rosa multiflora Nutrition 0.000 claims description 2
- 229910002114 biscuit porcelain Inorganic materials 0.000 claims description 2
- 229940082906 centella asiatica leaf extract Drugs 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- 235000014104 aloe vera supplement Nutrition 0.000 claims 1
- 230000001153 anti-wrinkle effect Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 7
- 239000002537 cosmetic Substances 0.000 abstract description 6
- 239000000419 plant extract Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 35
- 241000252212 Danio rerio Species 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 230000037303 wrinkles Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940100524 ethylhexylglycerin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 244000144927 Aloe barbadensis Species 0.000 description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960003993 chlorphenesin Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 238000007781 pre-processing Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 229960003885 sodium benzoate Drugs 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- 125000003184 C60 fullerene group Chemical group 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940074992 chondrus crispus extract Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108010008359 protein kinase C lambda Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 229940100459 steareth-20 Drugs 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/001—Preparations for care of the lips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
本申请涉及化妆品领域,公开了一种祛皱保湿眼部精华液及其制备方法。本申请所述精华液包括富勒烯原液、皮肤调理剂、保湿剂、增稠剂、螯合剂和溶剂;其中,所述富勒烯原液包含β‑丙氨酸修饰的富勒烯。本申请祛皱保湿眼部精华液采用富勒烯与包含多种天然植物提取物的皮肤调理剂和保湿剂等组分组合,通过各组分的协同作用,实现了较高的抗皱效果和保湿效果;同时,与使用常规羟基修饰的富勒烯相比,本申请通过β‑丙氨酸进行修饰,使眼部精华液在抗皱效果上得到了显著提高。
Description
技术领域
本申请涉及化妆品领域,尤其涉及一种祛皱保湿眼部精华液及其制备方法。
背景技术
皱纹是由于人体受到内源性及外源性因素的影响后,导致皮肤支撑组织及皮肤结构的变化,造成皮肤保水能力的丧失,弹力纤维和胶原排列顺序的变化,由此导致皮肤的机械力和弹性下降,形成凹陷,从而形成皱纹。
导致皮肤衰老的原因有很多,其中自由基理论是导致衰老的核心理论。自由基是机体正常代谢过程中的产物,反应能力很强,但过量的自由基会破坏正常细胞膜组织内的胶原蛋白及活性物质,使得皮肤真皮层胶原蛋白含量逐渐减少,网状支撑体亦会变厚变硬、失去弹性。当真皮层的弹性与保水度降低,皮肤便会失去弹性并变薄老化,表皮即形成松垮的皱纹。与此同时,随着年龄的增长,皮肤的保湿机构以及屏障修护系统也会受到损伤,皮肤组织细胞和细胞间的水分保持量会减少,当角质层的水分下降到10%以下时,皮肤就会显得干燥、失去弹性,会加速皮肤老化产生皱纹和色斑。
目前,市场上的抗衰老类化妆品多数以抗氧化、祛自由基为产品设计思路,以添加抗氧化成分如抗坏血酸及其衍生物、维生素E、富勒烯、光甘草定等来达成目标,但大部分产品的修复效果仍需要进一步提升。
发明内容
有鉴于此,本申请的目的在于提供一种祛皱保湿眼部精华液及其制备方法,使得所述眼部精华液不仅具有较高的抗皱效果,而且同时具有较佳的保湿功能。
为了解决上述技术问题/达到上述目的或者至少部分地解决上述技术问题/达到上述目的,本申请第一个方面提供了一种祛皱保湿眼部精华液,包括:富勒烯原液、皮肤调理剂、保湿剂、增稠剂、螯合剂和溶剂;其中,所述富勒烯原液包含β-丙氨酸修饰的富勒烯。
可选地,以质量百分比计,包括0.01-5%的富勒烯原液、1.43-42.5%的皮肤调理剂、1.42-20.8%的保湿剂、0.13-3.2%的增稠剂、0.12%的螯合剂,余量为溶剂。
可选地,所述富勒烯为由碳原子数n组成的笼状结构的富勒烯,60≤n≤100。
可选地,所述皮肤调理剂可选自绞股蓝提取物、棕榈酰四肽-7、N-羟基琥珀酸亚胺、橙皮苷甲基查尔酮、二肽-2、库拉索芦荟提取物、赤藓醇、交替单胞菌发酵产物提取物、水解胶原、精氨酸/赖氨酸多肽、洋蔷薇花提取物、素方花花提取物、雏菊花提取物、乙酰基四肽-5、精氨酸、皱波角叉菜提取物、积雪草叶提取物和厚朴树皮提取物中的一种或两种以上。
可选地,所述保湿剂选自甘油、甜菜碱、甘油聚丙烯酸酯、生物糖胶-1、辛酰羟肟酸、1,3-丙二醇、透明质酸钠和水解透明质酸钠中的一种或两种以上。
可选地,所述增稠剂选自丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、卡波姆中的一种或两种以上。
可选地,所述螯合剂选自EDTA和其钠盐中的一种或两种以上。
可选地,所述溶剂为水。
本申请第二个方面提供了所述眼部精华液的制备方法,包括:
步骤1、将部分保湿剂、部分皮肤调理剂、增稠剂、螯合剂和溶剂搅拌、加热、均质,使其完全溶解;
步骤2、逐步降温并加入剩余的保湿剂和皮肤调理剂,以及富勒烯原液,搅拌均匀,获得所述眼部精华液。
可选地,步骤1中加热为加热至83-85℃,步骤2中逐步降温为从步骤1中加热的目标温度逐渐降至30-35℃。
本申请祛皱保湿眼部精华液采用富勒烯与包含多种天然植物提取物的皮肤调理剂和保湿剂等组分组合,通过各组分的协同作用,实现了较高的抗皱效果和保湿效果;同时,与使用常规羟基修饰的富勒烯相比,本申请通过β-丙氨酸进行修饰,使眼部精华液在抗皱效果上得到了显著提高。
附图说明
图1所示为斑马鱼尾部面积表型图;虚线部位为定量区域,
图2所示为本申请眼部精华液与正常对照组的斑马鱼col1a1b基因相对表达量柱形图;与正常对照组比较,***p<0.001;
图3所示为β-丙氨酸修饰富勒烯的眼部精华液与羟基修饰富勒烯的眼部精华液的斑马鱼col1a1b基因相对表达量柱形图;与羟基修饰富勒烯组比较,**p<0.01。
具体实施方式
本申请公开了一种祛皱保湿眼部精华液及其制备方法,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本申请。本申请所述产品、工艺和应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本申请内容、精神和范围内对本文所述产品、工艺和应用进行改动或适当变更与组合,来实现和应用本申请技术。显然,所描述的实施例是本申请的一部分实施例,而不是全部的实施例。基于本申请中的实施例,本领域普通技术人员在没有做出创造性劳动的前提下所获得的所有其他实施例,都属于本申请保护的范围。
需要说明的是,在本文中,如若出现诸如“第一”和“第二”、“S1”和“S2”、“步骤1”和“步骤2”以及“(1)”和“(2)”等之类的关系术语仅仅用来将一个实体或者操作与另一个实体或操作区分开来,而不一定要求或者暗示这些实体或操作之间存在任何这种实际的关系或者顺序。而且,术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者设备所固有的要素。在没有更多限制的情况下,由语句“包括一个……”限定的要素,并不排除在包括所述要素的过程、方法、物品或者设备中还存在另外的相同要素。同时,在不冲突的情况下,本申请中的实施例及实施例中的特征可以相互组合。
在本申请的第一方面中,提供了一种祛皱保湿眼部精华液,包括:富勒烯原液、皮肤调理剂、保湿剂、增稠剂、螯合剂和溶剂;其中,所述富勒烯原液包含β-丙氨酸修饰的富勒烯。
富勒烯是一种非极性分子,具有强烈的疏水性,仅能够溶于对生物体有害的非极性有机溶剂如甲苯、苯、环己烷、氯仿中。富勒烯本身疏水性性质直接影响了其生物活性的发挥,为了更好的促进吸收,将富勒烯制成水溶性富勒烯。目前化妆品领域常用的水溶性改性方式为修饰羟基或使用聚乙二醇、聚乙烯吡咯烷酮或环糊精等进行包覆,前者一般将富勒烯与双氧水和碱溶液混合并进行反应,经过洗涤和透析,即可得到羟基修饰的水溶性富勒烯;后者一般是将富勒烯与聚乙二醇、聚乙烯吡咯烷酮或环糊精进行球磨或超声等就可以得到被包覆的水溶性富勒烯。而通过氨基酸修饰的水溶性富勒烯通常用于相关临床疾病的治疗中,用于提高化妆品抗皱效果尚未有相关报道。在本申请某些实施方式中,所述富勒烯原液包含β-丙氨酸修饰的富勒烯,其制备过程可参照专利CN112957373A中实施例1记载。
在本申请某些实施方式中,所述富勒烯原液除包含β-丙氨酸修饰的富勒烯之外,还可以包含一些保湿剂和溶剂,保湿剂如黄原胶、丁二醇等,溶剂如水;在本申请另外一些实施方式中,所述富勒烯原液以质量百分比计,包括0<β-丙氨酸修饰的富勒烯<1%、80%≤保湿剂<86%和余量溶剂;在本申请另外一些实施方式中,所述富勒烯原液以质量百分比计,包括80%≤丁二醇<85%、0<β-丙氨酸修饰的富勒烯<1%、0<黄原胶≤1%和余量水;
在本申请某些实施方式中,所述富勒烯为由碳原子数n组成的笼状结构的富勒烯,60≤n≤100,例如n为60、70、80、90或100。
在本申请某些实施方式中,以质量百分比计,包括0.01-5%的富勒烯原液、1.43-42.5%的皮肤调理剂、1.42-20.8%的保湿剂、0.13-3.2%的增稠剂、0.12%的螯合剂,余量为溶剂。
在本申请某些实施方式中,所述皮肤调理剂可选自绞股蓝提取物、棕榈酰四肽-7、N-羟基琥珀酸亚胺、橙皮苷甲基查尔酮、二肽-2、库拉索芦荟提取物、赤藓醇、交替单胞菌发酵产物提取物、水解胶原、精氨酸/赖氨酸多肽、洋蔷薇花提取物、素方花花提取物、雏菊花提取物、乙酰基四肽-5、精氨酸、皱波角叉菜提取物、积雪草叶提取物和厚朴树皮提取物中的一种或两种以上。
在本申请另外一些实施方式中,上述皮肤调理剂的各种选择可以单独或至少两种组合组成复合皮肤调理剂,或者在此基础上再添加保湿成分、溶剂、乳化剂、防腐剂、螯合剂等其他组份组成复合皮肤调理剂;其中,所述保湿成分包括但不限于丁二醇、1,2-己二醇、乙基己基甘油、黄原胶;所述溶剂包括但不限于异山梨醇酐二甲醚和水;所述乳化剂包括但不限于硬脂醇聚醚-20;所述防腐剂包括但不限于辛甘醇、苯氧乙醇、氯苯甘醚、乙基己基甘油、苯甲酸钠和山梨酸钾;所述螯合剂包括但不限于EDTA及其钠盐。
在本申请另外一些实施方式中,提供了如下表1所示的皮肤调理剂组合及其质量百分比:
表1
在本申请某些实施方式中,所述保湿剂选自甘油、甜菜碱、甘油聚丙烯酸酯、生物糖胶-1、辛酰羟肟酸、1,3-丙二醇、透明质酸钠和水解透明质酸钠中的一种或两种以上。
在本申请另外一些实施方式中,上述保湿剂的各种选择可以单独或至少两种组合组成复合保湿剂,或者在此基础上再添加溶剂、防腐剂等其他组份组成复合保湿剂;其中,所述溶剂包括但不限于水;所述防腐剂包括但不限于辛甘醇、苯氧乙醇、氯苯甘醚、乙基己基甘油、苯甲酸钠和山梨酸钾。
在本申请另外一些实施方式中,提供了如下表2所示的保湿剂组合及其质量百分比:
表2
在本申请某些实施方式中,所述增稠剂选自丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、卡波姆中的一种或两种以上;在本申请另外一些实施方式中,上述增稠剂的各种选择可以单独或至少两种组合组成复合增稠剂,或者在此基础上再添加溶剂比如水等组成复合增稠剂;在本申请另外一些实施方式中,所述增稠剂为三种,(1)丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物,占所述眼部精华液质量百分比为0.1-1%;(2)丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物和水(85-95%:5-15%),占所述眼部精华液质量百分比为0.01-2%;(3)卡波姆,占所述眼部精华液质量百分比为0.02-0.2%。
在本申请某些实施方式中,所述螯合剂选自EDTA和其钠盐中的一种或两种以上,占所述眼部精华液的质量百分比为0.12%;在本申请另外一些实施方式中,所述螯合剂为EDTA二钠。
在本申请某些实施方式中,所述溶剂为水。
本申请祛皱保湿眼部精华液采用斑马鱼为实验动物进行保湿和抗皱功效的验证,结果显示,相比较模型组和正常对照组,使用本申请祛皱保湿眼部精华液的斑马鱼保湿功效更高,达到70%;抗皱功效关联基因col1a1b基因相对表达量为1.79左右,相比正常对照组有极显著差异(p<0.001);
此外,按照常规工艺对C60富勒烯进行羟基改性,与通过β-丙氨酸改性的富勒烯进行抗皱效果的对比,结果显示,使用β-丙氨酸改性的富勒烯的抗皱效果要显著高于羟基改性的富勒烯(p<0.01)。
在本申请的第二个方面中,提供了所述眼部精华液的制备方法,包括:
步骤1、将部分保湿剂、部分皮肤调理剂、增稠剂、螯合剂和溶剂搅拌、加热、均质,使其完全溶解;
步骤2、逐步降温并加入剩余的保湿剂和皮肤调理剂,以及富勒烯原液,搅拌均匀,获得所述眼部精华液。
其中,所述部分保湿剂和部分皮肤调理剂根据物质组成性质选择,以表1和表2为例,部分皮肤调理剂为表1序号10的皮肤调理剂,部分保湿剂为序号为1、5-6的保湿剂;
在本申请某些实施方式中,步骤1中加热为加热至83-85℃,步骤2中逐步降温为从步骤1中加热的目标温度逐渐降至30-35℃。
在本申请某些实施方式中,逐步降温并加入剩余的保湿剂和皮肤调理剂根据物质组成性质,选择恰当的降温段加入;在本申请另外一些实施方式中,所述逐步降温分为降温至60-70℃、降温至45-55℃、降温至40-50℃、降温至35-40℃、降温至30-35℃五个阶段降温程序;
在本申请另外一些实施方式中,以表1和表2为例,步骤2包括:
步骤2.1、降温至60-70℃,加入精氨酸,搅拌均匀;
步骤2.2、降温至45-55℃,加入厚朴树皮提取物,搅拌均匀;
步骤2.3、降温至40-50℃,加入除前述步骤(含步骤1)已加入物质以及表2序号4的保湿剂之外的其他表1和表2组分,以及富勒烯原液,搅拌均匀;
步骤2.4、降温至35-40℃、加入表2序号4的保湿剂,搅拌均匀;
步骤2.5、降温至30-35℃,检测合格后,获得所述眼部精华液。
在本申请某些实施方式中,本申请提供了如下具体的制备方法:
(1)前置处理
预先将所用生产设备与称量工具全部清洁灭菌,备用;
生产配方中所用水均为经过高混灭菌的纯水,加热至85-90度,维持30min,备用;
将表1中E相分完全溶解,备用;将表1中B组分完全溶解,备用;
(2)制备过程
将表1和表2中A相所有组分以及增稠剂、螯合剂和水投入乳化锅中,开启搅拌35r/miin,并加热至83-85℃,均质速度2500RPM,时间8min,使其完全溶解,保温10min,降温;
温度降至65℃时,加入表1中B相组分,搅拌均匀,继续缓慢降温;
温度降至50℃时,缓慢加入表1的C相组分,继缓级慢降温;
温度降至45℃时,缓慢加入表1和表2的D相组分,继续缓慢降温;
温度降至38℃时,缓慢加入表2的E相组分,继续缓慢降温;
温度降至32度时检测合格后,即可出料完成制备。
在本申请提供的各组对比实验中,如未特别说明,除各组指出的区别外,其他实验条件、材料等均保持一致,以便具有可对比性。本申请中所用组分均可以通过现有工艺制备或通过市售途径购买,以各天然提取物为例,均可以通过水或乙醇加以提取获得对应的提取物。
以下就本申请所提供的一种祛皱保湿眼部精华液及其制备方法做进一步说明。
实施例1:本申请祛皱保湿眼部精华液
1、配方
表3
2、制备方法
(1)前置处理
预先将所用生产设备与称量工具全部清洁灭菌,备用;
生产配方中所用水均为经过高混灭菌的纯水,加热至85-90度,维持30min,备用;
将表3中E相分完全溶解,备用;将表3中B组分完全溶解,备用;
(2)制备过程
将表3中A相所有组分投入乳化锅中,开启搅拌35r/miin,并加热至83-85℃,均质速度2500RPM,时间8min,使其完全溶解,保温10min,降温;
温度降至65℃时,加入B相组分,搅拌均匀,继续缓慢降温;
温度降至50℃时,缓慢加入表3的C相组分,继缓级慢降温;
温度降至45℃时,缓慢加入表3的D相组分,继续缓慢降温;
温度降至38℃时,缓慢加入表3的E相组分,继续缓慢降温;
温度降至32度时检测合格后,即可出料完成制备。
实施例2:本申请祛皱保湿眼部精华液保湿和抗皱效果验证
1、保湿功效验证
斑马鱼用氯化钠处理,由于渗透压的原因皮肤表面将会失水皱缩,尾部面积因皱缩而变小,通过对尾部面积的影响评价化妆品的保湿效果。
试验体系:黑色素等位基因突变半透明Albino品系斑马鱼;斑马鱼鱼龄:受精后2天(2dpf);每组实验样本量:15尾(取样观察N=10)。
实验方法:
(1)随机选取斑马鱼于6孔板中,每孔15尾。
(2)水溶给予样品,同时设置正常对照组和模型对照组,每孔容量为3mL。
(3)同时水溶给予氯化钠建立斑马鱼皮肤缺水模型。
(4)28℃条件下避光孵育22h。
(5)每个实验组随机选取10尾斑马鱼置于解剖显微镜下拍照,用高级图像处理软件分析并采集数据,分析斑马鱼尾部面积(S),根据公式计算样品的保湿功效,判断其是否具有保湿功效;
结果见表4和图1;
表4
检测项目 | 检测浓度(%) | 功效(%) | P值 | 检测结果 |
保湿功效 | 0.5 | 70 | <0.001 | 显著 |
观察发现,本申请祛皱保湿眼部精华液的尾部面积与模型对照组相比,明显增加,与未摄入氯化钠的正常对照组比较相似,尾部没有明显皱缩,表明本申请祛皱保湿眼部精华液具有显著的保湿功效。
2、抗皱功效验证
皮肤的生长、修复、营养以及弹性、张力都与胶原蛋白有关,它的流失会使皮肤光滑度下降,产生皱纹。在四足动物中,I型胶原蛋白是一个三聚体,主要由两个α1链和一个α2链组成,分别由col1a1a和col1a2基因编码,在结缔组织和骨中执行胶原蛋白相关生物功能。在斑马鱼中存在三种I型胶原基因,分别编码α1(I)、α2(I)和α3(I)链的col1a1a、col1a1b和col1a2。因此,通过检测col1a1a或(和)col1a1b或(和)col1a2基因相对表达量可表明样品是否具有抗皱功效,本次实验检测col1a1b基因。
试验体系:野生型AB品系斑马鱼。斑马鱼鱼龄:受精后4天(4dpf)。每组实验样本量:30尾(三次生物学重复,N=3)。
实验方法:
(1)随机选取斑马鱼于6孔板中,每孔30尾。
(2)水溶给予样品,同时设置正常对照组,每孔容量为3mL。三次生物学重复。
(3)28℃条件下避光孵育24h。
(4)提取各实验组斑马鱼总RNA,合成cDNA,利用q-PCR检测β-actin和目的基因的基因表达。
(5)用β-actin作为基因表达的内参,计算目的基因的RNA相对表达量(2△△Ct法)。
RNA相对表达量=2ΔΔC(t)
ΔΔC(t)=ΔC(t)正常对照组-ΔC(t)样品组
ΔC(t)=C(t)目的基因-C(t)β-action
结果见表5和图2;
表5
观察发现,本申请除皱保湿眼部精华液的col1a1b基因相对表达量与正常对照组相比明显增加,表明本申请祛皱保湿眼部精华液具有显著的抗皱功效。
实施例3:不同修饰的富勒烯对抗皱效果的影响
将C60富勒烯与双氧水和碱溶液混合并进行反应,经过洗涤和透析,得到羟基修饰的水溶性富勒烯,参照表3配方替换本申请β-丙氨酸修饰的C60富勒烯,按照实施例2中的方法进行对比,结果见图3;由图3可以明显看出,将经过β-丙氨酸修饰富勒烯用于抗皱方面可以比常规羟基修饰的富勒烯有更高的抗皱效果。
以上所述仅是本申请的具体实施方式,使本领域技术人员能够理解或实现本申请。对这些实施例的多种修改对本领域的技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本申请的精神或范围的情况下,在其它实施例中实现。因此,本申请将不会被限制于本文所示的这些实施例,而是要符合与本文所申请的原理和新颖特点相一致的最宽的范围。
Claims (10)
1.一种祛皱保湿眼部精华液,其特征在于,包括:富勒烯原液、皮肤调理剂、保湿剂、增稠剂、螯合剂和溶剂;其中,所述富勒烯原液包含β-丙氨酸修饰的富勒烯。
2.根据权利要求1所述眼部精华液,其特征在于,以质量百分比计,包括0.01-5%的富勒烯原液、1.43-42.5%的皮肤调理剂、1.42-20.8%的保湿剂、0.13-3.2%的增稠剂、0.12%的螯合剂,余量为溶剂。
3.根据权利要求1或2所述眼部精华液,其特征在于,所述富勒烯为由碳原子数n组成的笼状结构的富勒烯,60≤n≤100。
4.根据权利要求1或2所述眼部精华液,其特征在于,所述皮肤调理剂选自绞股蓝提取物、棕榈酰四肽-7、N-羟基琥珀酸亚胺、橙皮苷甲基查尔酮、二肽-2、库拉索芦荟提取物、赤藓醇、交替单胞菌发酵产物提取物、水解胶原、精氨酸/赖氨酸多肽、洋蔷薇花提取物、素方花花提取物、雏菊花提取物、乙酰基四肽-5、精氨酸、皱波角叉菜提取物、积雪草叶提取物和厚朴树皮提取物中的一种或两种以上。
5.根据权利要求1或2所述眼部精华液,其特征在于,所述保湿剂选自甘油、甜菜碱、甘油聚丙烯酸酯、生物糖胶-1、辛酰羟肟酸、1,3-丙二醇、透明质酸钠和水解透明质酸钠中的一种或两种以上。
6.根据权利要求1或2所述眼部精华液,其特征在于,所述增稠剂选自丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、卡波姆中的一种或两种以上。
7.根据权利要求1或2所述眼部精华液,其特征在于,所述螯合剂选自EDTA和其钠盐中的一种或两种以上。
8.根据权利要求1或2所述眼部精华液,其特征在于,所述溶剂为水。
9.权利要求1所述眼部精华液的制备方法,其特征在于,包括:
步骤1、将部分保湿剂、部分皮肤调理剂、增稠剂、螯合剂和溶剂搅拌、加热、均质,使其完全溶解;
步骤2、逐步降温并加入剩余的保湿剂和皮肤调理剂,以及富勒烯原液,搅拌均匀,获得所述眼部精华液。
10.根据权利要求8所述制备方法,其特征在于,步骤1中加热为加热至83-85℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210958430.9A CN115252521A (zh) | 2022-08-09 | 2022-08-09 | 一种祛皱保湿眼部精华液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210958430.9A CN115252521A (zh) | 2022-08-09 | 2022-08-09 | 一种祛皱保湿眼部精华液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115252521A true CN115252521A (zh) | 2022-11-01 |
Family
ID=83750798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210958430.9A Pending CN115252521A (zh) | 2022-08-09 | 2022-08-09 | 一种祛皱保湿眼部精华液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115252521A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004269523A (ja) * | 2003-02-20 | 2004-09-30 | Shinobu Ito | フラーレン外用組成物 |
CN1753968A (zh) * | 2003-01-27 | 2006-03-29 | 三菱商事株式会社 | 抗氧化组合物以及外用组合物 |
JP2008143783A (ja) * | 2006-12-05 | 2008-06-26 | Vitamin C60 Bioresearch Kk | 毛穴引き締め剤 |
CN109316363A (zh) * | 2018-12-07 | 2019-02-12 | 北京富乐喜科技有限公司 | 一种利用富勒烯制备具有保湿、抗衰老功能的护肤剂的方法 |
CN110075020A (zh) * | 2019-04-25 | 2019-08-02 | 广州科恩生物技术有限公司 | 一种富勒烯抗皱精华液及其制备方法 |
CN114404308A (zh) * | 2021-12-01 | 2022-04-29 | 广州雷诺生物科技有限公司 | 一种富勒烯保湿美白修护精华液及其制备方法 |
-
2022
- 2022-08-09 CN CN202210958430.9A patent/CN115252521A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1753968A (zh) * | 2003-01-27 | 2006-03-29 | 三菱商事株式会社 | 抗氧化组合物以及外用组合物 |
US20060134095A1 (en) * | 2003-01-27 | 2006-06-22 | Shinobu Ito | Antioxidative composition and composition for external use |
JP2004269523A (ja) * | 2003-02-20 | 2004-09-30 | Shinobu Ito | フラーレン外用組成物 |
JP2008143783A (ja) * | 2006-12-05 | 2008-06-26 | Vitamin C60 Bioresearch Kk | 毛穴引き締め剤 |
CN109316363A (zh) * | 2018-12-07 | 2019-02-12 | 北京富乐喜科技有限公司 | 一种利用富勒烯制备具有保湿、抗衰老功能的护肤剂的方法 |
CN110075020A (zh) * | 2019-04-25 | 2019-08-02 | 广州科恩生物技术有限公司 | 一种富勒烯抗皱精华液及其制备方法 |
CN114404308A (zh) * | 2021-12-01 | 2022-04-29 | 广州雷诺生物科技有限公司 | 一种富勒烯保湿美白修护精华液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021020887A (ja) | 強化されたアンチエイジング化粧品組成物 | |
CN110731923B (zh) | 增强的保湿化妆品组合物 | |
JP2021020886A (ja) | アンチエイジング化粧品組成物 | |
CN110693807B (zh) | 一种肌底精华液及其制备方法 | |
CN113116755A (zh) | 一种促渗透的护肤组合物及其制备方法和应用 | |
EP2822660A2 (en) | Composition for treating skin pigmentation | |
CN106691945A (zh) | 一种含有五味子提取物的抗氧化面膜 | |
CN110731926A (zh) | 保湿化妆品组合物 | |
CN110215423A (zh) | 含有多种植物提取物的修复抗衰组合物、制备方法及应用 | |
CN111840176A (zh) | 一种具有抗糖基化、美白、祛斑、祛皱作用的美容组合物及其应用 | |
CN114588061A (zh) | 一种抗衰除皱组合物及其制备方法和护肤品 | |
CN114948787A (zh) | 一种皮肤保湿组合物、含有该组合物的化妆品及制备方法 | |
CN113633599B (zh) | 一种含铁皮石斛提取物的肌底精华液及其制备方法 | |
CN115317424A (zh) | 一种祛皱保湿眼霜及其制备方法 | |
CN112107512B (zh) | 一种含有灵芝子实体孢子粉发酵液的头皮精华及其制备方法 | |
CN111904909B (zh) | 一种含有玫瑰发酵液的去屑头皮精华及其制备方法 | |
KR102611827B1 (ko) | 식물 추출 방법 | |
CN105943427A (zh) | 一种含牡丹籽油的多效滋润眼霜及其制备方法 | |
CN112137895A (zh) | 一种含银耳多糖的眼膜及其制备方法 | |
CN115569106B (zh) | 螺旋藻h11株系水提取物及其制备方法、应用和护肤品 | |
CN115252521A (zh) | 一种祛皱保湿眼部精华液及其制备方法 | |
KR102140185B1 (ko) | 천연물 유래 발효추출물 발모제를 포함하는 하이드로젤 나노입자, 이의 제조방법 | |
CN110585079A (zh) | 一种含食源肽的抗辐射组合物及其抗辐射乳液 | |
CN114272165B (zh) | 美白紧致植物精华护肤乳液及其制备方法 | |
CN113456513A (zh) | 一种含有虾青素包合物的贴片式面膜及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20221101 |